Hodgkin lymphoma (C81)

The following material has been sourced from the Australian Institute of Health and Welfare

Table B11(a): Incidence and mortality of Hodgkin lymphoma
2011 incidence/2012 mortality(b)   Incidence - Males Incidence - Females Incidence - Persons Mortality - Males Mortality - Females Mortality - Persons
Number 338 268 606 55 23 78
Crude rate 3.0 2.4 2.7 0.5 0.2 0.3
ASR 3.0 2.3 2.7 0.5 0.2 0.3
Risk to age 75 1 in 437 1 in 596 1 in 505 1 in 3,791 1 in 11,785 1 in 5,784
Risk to age 85 1 in 361 1 in 479 1 in 412 1 in 1,546 1 in 5,655 1 in 2,533
Mean age 43.4 42.4 43.0 71.3 64.8 69.4
 
Estimated number for 2014, 2015 and 2016(c)   Incidence - Males Incidence - Females Incidence - Persons Mortality - Males Mortality - Females Mortality - Persons
2014 335 265 605 15 15 30
2015 345 270 615 15 15 30
2016 350 275 630 15 15 30

Figure B11(a): Incidence and mortality ASRs(b,c) of Hodgkin lymphoma, 1982-2016

Line chart showing rate (per 100,000 people) of incidence and mortality of Hodgkin lymphoma in males and females from 1982 to 2012, with estimates to 2016.

Figure B11(b): Incidence (2011) and mortality (2012) rates of Hodgkin lymphoma, by age group

Line chart showing rate (per 100,000 people) of incidence (2011) and mortality (2012) of Hodgkin lymphoma in males and females by age group. Age groups shown are: 0-4, 10-14, 20-24, 30-34, 40-44, 50-54, 60-64, 70-74 and 80-84.
  1. Based on IARC (2014) and WCRF & AICR (2007) (see Chapter 2).
  2. The 2011 incidence data include estimates for NSW and the ACT. Mean age for 2011 incidence was calculated excluding NSW and the ACT (see Appendix F, Cancer in Australia: an overview 2014). Deaths registered in 2010 and earlier are based on the final version of cause of death data; deaths registered in 2011 and 2012 are based on revised and preliminary versions, respectively, and are subject to further revision by the ABS. ASRs were directly standardised to the Australian population as at 30 June 2001. Rates are expressed per 100,000 population.
  3. The 2012–2016 estimates for incidence are based on 2002–2011 incidence data. The 2013–2016 estimates for mortality are based on 2002–2012 mortality data (see Appendix G, Cancer in Australia: an overview 2014). They are rounded to the nearest 10. Estimates less than 1,000 are rounded to the nearest 5. The estimates for males and females may not add to estimates for persons due to rounding.

Sources: AIHW ACD 2011; AIHW NMD.

Table B11(b): Survival and prevalence of Hodgkin lymphoma
Prevalence as at the end of 2009(a)   Males Females Persons
1-year prevalence 281 251 532
5-year prevalence 1,281 1,087 2,368
 
Relative survival in 2007-2011(b)   Males Females Persons
1-year relative survival at diagnosis (%) 93.8 92.9 93.4
95% confidence interval 92.3-95.1 91.2-94.4 92.3-94.4
5-year relative survival at diagnosis (%) 87.3 87.1 87.2
95% confidence interval 85.1-89.2 84.8-89.1 85.7-88.6
5-year conditional relative survival for those already survived 1 year after diagnosis (%) 91.9 92.9 92.4
95% confidence interval 90.3-93.6 91.3-94.5 91.2-93.5
5-year conditional relative survival for those already survived 5 years after diagnosis (%) 94.9 95.7 95.3
95% confidence interval 93.4-96.4 94.2-97.1 94.2-96.3

Figure B11(c): Relative survival at diagnosis and 5-year conditional survival from Hodgkin lymphoma, Australia, 2007–2011

Line chart showing rate of relative survival of Hodgkin lymphoma from 2007 to 2011 by years after diagnosis. Survival rates are grouped by relative survival at diagnosis and 5-year conditional relative survival. Survival rates drop steadily over 20 years for relative survival at diagnosis; while 5-year conditional relative survival rates slowly increase over a period of 15 years. Neither drop below 70% over a 20-year period.
  1. Prevalence refers to the number of living people previously diagnosed with cancer, not the number of cancer cases.
  2. Relative survival was calculated with the period method, using the period 2007-2011 (Brenner & Gefeller 1996). Note that this period does not contain incidence data for 2010-2011 for NSW or the ACT (see Appendix F, Cancer in Australia: an overview 2014).

Source: AIHW ACD 2011.